L3VLUP
ProSign in

ADPT in the 13F filings

Adaptive Biotechnologies Corp · CUSIP 00650F109

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Dec 2024
the date the book describes
Filed
14 Feb 2025
latest of these filings; the earliest 4 Feb 2025
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q3 2024 and Q4 2024; 3 listed it in both
Shares listed
39,857,350
combined, among listed positions
Reported value
$239m
combined, at the quarter end

Among the 94 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was -2,017,874.

Managers listing ADPT in Q4 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Viking Global Investors LP29,993,708$180m0.58%Held014 Feb 2025 (the filing on sec.gov)
ARK Investment Management LLC9,424,074$56m0.47%Trimmed-2,177,0604 Feb 2025 (the filing on sec.gov)
PDT Partners LLC316,281$1.9m0.17%Added+35,89914 Feb 2025 (the filing on sec.gov)
Caxton Associates LLP123,287$739kunder 0.1%Newnew14 Feb 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2024 to Q4 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 7 in Q2 2026

Tracked managers listing it, at least.

0510152020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ADPT by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20198$1.9bnn.a.n.a.
Q3 20192$1.2bnn.a.n.a.
Q4 20195$1.2bnn.a.n.a.
Q1 20204$1.1bnn.a.n.a.
Q2 20208$1.9bnn.a.n.a.
Q3 202011$2.2bnn.a.n.a.
Q4 202010$2.7bnn.a.n.a.
Q1 20216$1.9bnn.a.n.a.
Q2 20217$2.0bnn.a.n.a.
Q3 20217$1.7bnn.a.n.a.
Q4 20217$1.5bnn.a.n.a.
Q1 20225$525mn.a.n.a.
Q2 20223$311mn.a.n.a.
Q3 20223$281mn.a.n.a.
Q4 20223$300mn.a.n.a.
Q1 20233$347mn.a.n.a.
Q2 20233$272mn.a.n.a.
Q3 20234$262mn.a.n.a.
Q4 20235$232m22
Q1 20243$131m11
Q2 20243$151m10
Q3 20243$214m20
Q4 20244$239m21
Q1 20253$283m11
Q2 20255$404m22
Q3 20255$503m22
Q4 20256$535m2113
Q1 20266$457m1914
Q2 20267$946m1220

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ADPT and GILD →ADPT and AMGN →ADPT and ARGX →Choose a stock to compare with ADPT →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ADPT, latest filings →Back to the 13F Explorer →